Apotex Health Corp. (TSX:APTX)

Revenue by Segment

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Conventional Generics	1.78B	1.87B	1.79B
Conventional Generics Growth	-4.90%	4.81%	-
Specialty Generics	1.15B	976.30M	784.21M
Specialty Generics Growth	17.94%	24.49%	-
Brands & Biosimilars	558.70M	500.96M	369.76M
Brands & Biosimilars Growth	11.53%	35.48%	-
Total	3.49B	3.35B	2.94B
Total Growth	4.21%	13.92%	-

Revenue by Geography

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Canada	1.43B	1.27B	1.08B
Canada Growth	12.88%	17.43%	-
United States (U.S.)	1.79B	1.81B	1.58B
United States (U.S.) Growth	-1.13%	14.69%	-
International	269.38M	271.05M	282.02M
International Growth	-0.62%	-3.89%	-
Total	3.49B	3.35B	2.94B
Total Growth	4.21%	13.92%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jul 2, 2026

Data Sources Report a data error